Navigation Links
AtriCure to Present at the BMO Focus on Healthcare and Canaccord Adams Global Growth Conferences in August
Date:7/31/2008

WEST CHESTER, Ohio, July 31 /PRNewswire-FirstCall/ -- AtriCure, Inc. (Nasdaq: ATRC), a medical device company and a leader in cardiac surgical ablation systems, today announced that it will present at the following investor conferences during August:

-- The BMO Focus on Healthcare Conference, Wednesday, August 6, 2008 at

the Millennium Broadway Hotel in New York. David J. Drachman, President

and Chief Executive Officer, is scheduled to present at 9:00 a.m.

Eastern time.

-- The Canaccord Adams Global Growth Conference, Wednesday, August 13,

2008 at the Intercontinental Hotel in Boston. Mr. Drachman is scheduled

to present at 10:30 a.m. Eastern time.

Both presentations will be available for replay for 30 days following the presentations at http://www.atricure.com/Investor_Relations

About AtriCure, Inc.

AtriCure, Inc. is a medical device company and a leader in developing, manufacturing and selling innovative cardiac surgical ablation systems designed to create precise lesions, or scars, in cardiac, or heart, tissue. Medical journals have described the adoption by leading cardiothoracic surgeons of the AtriCure Isolator(R) bipolar ablation system as a treatment alternative during open-heart surgical procedures to create lesions in cardiac tissue to block the abnormal electrical impulses that cause atrial fibrillation, or AF, a rapid, irregular quivering of the upper chambers of the heart. Additionally, medical journals and leading cardiothoracic surgeons have described the AtriCure Isolator(R) system as a promising treatment alternative for patients who may be candidates for sole-therapy minimally invasive procedures. AF affects more than 5.5 million people worldwide and predisposes them to a five-fold increased risk of stroke.

The FDA has cleared the AtriCure Isolator(R) system, including its Isolator Synergy(TM) ablation clamps, and AtriCure's multifunctional pen and Coolrail(TM) linear ablation device, for the ablation, or destruction, of cardiac tissue during surgical procedures. Additionally, the FDA has cleared AtriCure's multifunctional pen for temporary pacing, sensing, stimulating and recording during the evaluation of cardiac arrhythmias. To date, the FDA has not cleared or approved AtriCure's products for the treatment of AF. AtriCure's left atrial appendage clip system has not been approved for commercial use.

Contact:

AtriCure, Inc.

Julie A. Piton

Vice President and Chief Financial Officer

(513) 755-4561

jpiton@atricure.com


'/>"/>
SOURCE AtriCure, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. The AtriCure Minimally Invasive Platform Highlighted by Prominent Cardiac Surgeons and Electrophysiologists at Cardiostim in Nice, France
2. AtriCure Announces Web Cast and Conference Call of First Quarter 2008 Financial Results
3. AtriCures Coolrail(TM) Linear Ablation Pen Receives FDA 510(k) Clearance
4. AtriCure Reports Fourth Quarter and Full Year 2007 Record Financial Results
5. AtriCure to Present at Roth Capital Partners 20th Annual OC Conference
6. AtriCure Appoints Mark A. Collar to its Board of Directors
7. AtriCure Announces Web Cast and Conference Call of Fourth Quarter and Full Year 2007 Financial Results
8. AtriCure to Present at BMO Capital Markets 2007 Healthcare Conference
9. AtriCure Reports Third Quarter 2007 Financial Results
10. AtriCure Ranked 80th in Deloittes Technology Fast 500
11. AtriCure Announces Web Cast and Conference Call of Third Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... 2016 , ... They are musicians and librarians, fashion designers and fitness instructors, ... New England and around the nation. What do they have in common? All have ... beautiful and compelling new photographic exhibit debuting Friday, December 9 at Logan International Airport ...
(Date:12/7/2016)... ... 2016 , ... Augustine Insurance Agency, a locally owned and ... in the greater Dallas metropolitan area, is announcing a charity event that promises ... in 2009 by active police professionals in the Dallas region, the Dallas Fallen ...
(Date:12/7/2016)... Grants Pass, OR (PRWEB) , ... December 07, 2016 , ... ... Power of Water, Global Climate Change and Your Health on Voice of America, declared ... bullying, and to call attention to the fact that when these bullies attack leaders ...
(Date:12/7/2016)... ... December 07, 2016 , ... 1105 ... Winner in the Folio: Marketing Awards competition. Live From won in the Use ... pioneering, inventive, and ultimately successful projects undertaken by the media industry’s most innovative ...
(Date:12/7/2016)... Norwalk, CT (PRWEB) , ... December 07, 2016 ... ... the Integrated Infertility and Wellness (IFW) Program at Reproductive Medicine Associates of Connecticut ... which now has a team of three acupuncturists to help patients realize their ...
Breaking Medicine News(10 mins):
(Date:12/6/2016)... With opioids commonly used for pain management for workplace ... that has led to nationwide fatalities. The synthetic opioid ... than heroin or morphine, resulting in likelihood of addiction, abuse or ... , , ... operations, Behavioral Health for HMC HealthWorks, explained the opioid drug is ...
(Date:12/6/2016)... Dec. 6, 2016  Viking Therapeutics, Inc. ("Viking") ... company focused on the development of novel therapies ... the U.S. Food and Drug Administration (FDA) has ... treatment of X-linked adrenoleukodystrophy (X-ALD).  VK0214 is a ... that selectively regulates the expression of genes believed ...
(Date:12/6/2016)... Mass. , Dec. 6, 2016  Blueprint Medicines ... discovering and developing targeted kinase medicines for patients with ... an underwritten public offering of $125,000,000 million in shares ... to grant the underwriters a 30-day option to purchase ... of its common stock in connection with the public ...
Breaking Medicine Technology: